CeriBell (NASDAQ:CBLL) Director William Burke Sells 2,207 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 2,207 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total transaction of $43,786.88. Following the completion of the sale, the director owned 23,022 shares of the company’s stock, valued at approximately $456,756.48. The trade was a 8.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

CeriBell Stock Performance

CBLL stock traded down $0.25 during trading on Thursday, reaching $19.75. 588,020 shares of the stock were exchanged, compared to its average volume of 328,686. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $749.34 million, a P/E ratio of -12.18 and a beta of 0.84. The stock has a 50 day simple moving average of $18.84 and a 200-day simple moving average of $19.73.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The firm had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. As a group, sell-side analysts anticipate that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Hedge Funds Weigh In On CeriBell

A number of hedge funds have recently modified their holdings of CBLL. Strs Ohio bought a new position in shares of CeriBell during the 1st quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd raised its stake in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the third quarter worth $33,000. CWM LLC lifted its holdings in shares of CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on CBLL shares. Canaccord Genuity Group decreased their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.